Anebulo Pharmaceuticals Inc (ANEB)
1.84
-0.04
(-2.13%)
USD |
NASDAQ |
Nov 01, 16:00
Anebulo Pharmaceuticals Enterprise Value: 44.62M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 44.62M |
| October 31, 2024 | 45.66M |
| October 30, 2024 | 44.88M |
| October 29, 2024 | 46.05M |
| October 28, 2024 | 44.36M |
| October 25, 2024 | 44.36M |
| October 24, 2024 | 46.18M |
| October 23, 2024 | 45.92M |
| October 22, 2024 | 44.64M |
| October 21, 2024 | 45.14M |
| October 18, 2024 | 47.77M |
| October 17, 2024 | 44.36M |
| October 16, 2024 | 45.92M |
| October 15, 2024 | 46.18M |
| October 14, 2024 | 44.36M |
| October 11, 2024 | 45.66M |
| October 10, 2024 | 45.40M |
| October 09, 2024 | 47.48M |
| October 08, 2024 | 45.92M |
| October 07, 2024 | 46.58M |
| October 04, 2024 | 47.48M |
| October 03, 2024 | 46.44M |
| October 02, 2024 | 48.25M |
| October 01, 2024 | 48.38M |
| September 30, 2024 | 46.96M |
| Date | Value |
|---|---|
| September 27, 2024 | 50.07M |
| September 26, 2024 | 47.73M |
| September 25, 2024 | 44.88M |
| September 24, 2024 | 51.11M |
| September 23, 2024 | 54.48M |
| September 20, 2024 | 76.78M |
| September 19, 2024 | 50.85M |
| September 18, 2024 | 48.77M |
| September 17, 2024 | 55.77M |
| September 16, 2024 | 51.11M |
| September 13, 2024 | 50.85M |
| September 12, 2024 | 51.11M |
| September 11, 2024 | 42.81M |
| September 10, 2024 | 46.96M |
| September 09, 2024 | 46.44M |
| September 06, 2024 | 43.58M |
| September 05, 2024 | 43.59M |
| September 04, 2024 | 45.66M |
| September 03, 2024 | 43.84M |
| August 30, 2024 | 46.70M |
| August 29, 2024 | 44.26M |
| August 28, 2024 | 44.26M |
| August 27, 2024 | 49.55M |
| August 26, 2024 | 47.35M |
| August 23, 2024 | 51.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.67M
Minimum
Oct 21 2022
204.93M
Maximum
May 21 2021
80.82M
Average
60.53M
Median
Aug 18 2023
Enterprise Value Benchmarks
| Revance Therapeutics Inc | 802.59M |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
| iBio Inc | 9.837M |
| Theriva Biologics Inc | -12.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.35M |
| Total Expenses (Quarterly) | 1.340M |
| EPS Diluted (Quarterly) | -0.05 |
| Earnings Yield | -17.39% |